Young Mog Shim

Dr. Young Mog Shim


Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 May 2015 in European Radiology
Verified
Journal Article
Closed access
PDF file
JSJi Ye Son
Ji Ye Son
HLHo Yun Lee
Ho Yun Lee
JKJae-Hun Kim
Jae-Hun Kim
JHJoungho Han
Joungho Han
JJJi Yun Jeong
Ji Yun Jeong
YSYoung Mog Shim
Young Mog Shim

11 April 2019 in BMC Surgery
Verified
Journal Article
Open access
PDF file
YMYang Won Min
Yang Won Min
TKTaewan Kim
Taewan Kim
Hyuk LeeHyuk Lee
Hyuk Lee
BMByung-Hoon Min
Byung-Hoon Min
HKHong Kwan Kim
Hong Kwan Kim
YSYoung Mog Shim
Young Mog Shim
Anastomotic leak is the most common and serious complication following esophagectomy. Endoscopic vacuum-assisted closure (EVAC) is a promising method for treating anastomotic leak. We aimed to evaluate the efficacy of EVAC and to identify factors associated with longer treatment duration for esophageal anastomotic leak following esophagectomy for cancer. We retrospectively analyzed 20 esophageal cancer patients who had undergone EVAC for anastomotic leak after esophagectomy. The efficacy and success rates were evaluated and factors associated with longer treatment duration (≥ 21 days) were identified. All 20 patients were male. Of these, 10 (50.0%) received neoadjuvant treatment and 6 (30.0%) had one or more comorbidities. The median size of fistula opening was 1.75 cm. During a median of 14.5 days of EVAC treatment, a median of 5 interventions were performed. Treatment success was achieved in 19 patients (95.0%). Neoadjuvant treatment was significantly associated with longer EVAC treatment. There was a non-significant trend toward the need for longer treatment duration for a larger fistula opening size. EVAC treatment is a good non-surgical option for anastomotic leak following esophagectomy. Long duration of treatment is associated with neoadjuvant treatment and a large leakage opening.

10 April 2020 in Cancers
Verified
Journal Article
Open access
PDF file
HYHan Gyul Yoon
Han Gyul Yoon
DODongryul Oh
Dongryul Oh
YAYong Chan Ahn
Yong Chan Ahn
JNJae Myoung Noh
Jae Myoung Noh
HPHongryull Pyo
Hongryull Pyo
YSYoung Mog Shim
Young Mog Shim
Backgrounds: The relationship between sarcopenia, characterized by loss of muscle mass and strength, and survival outcomes of esophageal cancer is controversial. This study aimed to assess the effect of sarcopenia and skeletal muscle loss on overall survival (OS) and recurrence-free survival (RFS) of esophageal cancer patients. Methods: We retrospectively collected the medical records of 248 male patients diagnosed with squamous cell esophageal cancer and who underwent neoadjuvant chemoradiotherapy (NACRT) followed by surgery. We measured the cross-sectional area of the skeletal muscle at the L3 vertebra level using computed tomography images and calculated the skeletal muscle index (SMI). Sarcopenia was defined as SMI <52.4 cm2/m2, and excessive muscle loss was defined as SMI change <−10.0%/50 days during NACRT. Moreover, laboratory test results, such as albumin, prognostic nutritional index (PNI), neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio (PLR) before and after NACRT, were collected. Results: In the univariable Cox analysis, pre- (p = 0.689) and post-radiotherapy (RT) sarcopenia (p = 0.669) were not associated with OS. However, excessive muscle loss had a significant association with OS in both the univariable and multivariable analyses (all p = 0.001). Excessive muscle loss was also related to RFS in both the univariable (p = 0.011) and multivariable (p = 0.022) Cox analysis. Patients with excessive muscle loss had significantly lower levels of post-RT albumin (p < 0.001) and PNI (p < 0.001), higher levels of post-RT NLR (p = 0.031) and PLR (p = 0.071), larger decrease in albumin (p < 0.001) and PNI (p < 0.001) after NACRT, and larger increase in NLR (p = 0.051) and PLR (p = 0.088) after NACRT than in those with non-excessive muscle loss. Conclusion: Excessive muscle loss rather than pre- and post-RT sarcopenia was a significant prognostic factor for OS and RFS, and it was also related to nutritional and inflammatory markers.

5 April 2021 in Psycho-Oncology
Verified
Journal Article
Closed access
PDF file
SSSungkeun Shim
Sungkeun Shim
DKDanbee Kang
Danbee Kang
KBKa Ryeong Bae
Ka Ryeong Bae
WLWoo Yong Lee
Woo Yong Lee
SNSeok Jin Nam
Seok Jin Nam
JCJuhee Cho
Juhee Cho

21 November 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
JBJung Min Bae
Jung Min Bae
JJJi Yun Jeong
Ji Yun Jeong
HLHo Yun Lee
Ho Yun Lee
ISInsuk Sohn
Insuk Sohn
HKHye Seung Kim
Hye Seung Kim
YSYoung Mog Shim
Young Mog Shim
Pathologic stratification of operable lung adenocarcinoma using radiomics features extracted from dual energy CT images Pathologic stratification of operable lung adenocarcinoma using radiomics features extracted from dual energy ct images

27 August 2021 in Journal of Medical Internet Research
Verified
Journal Article
Open access
KYKyungmi Yang
Kyungmi Yang
DODongryul Oh
Dongryul Oh
JNJae Myoung Noh
Jae Myoung Noh
HYHan Gyul Yoon
Han Gyul Yoon
JSJong-Mu Sun
Jong-Mu Sun
YKYoungin Kim
Youngin Kim
Background: Excessive muscle loss is an important prognostic factor in esophageal cancer patients undergoing neoadjuvant chemoradiotherapy (NACRT), as reported in our previous research. Objective: In this pilot study, we prospectively tested the feasibility of a health coaching mobile app for preventing malnutrition and muscle loss in this patient population. Methods: Between July 2019 and May 2020, we enrolled 38 male patients with esophageal cancer scheduled for NACRT. For 8 weeks from the start of radiotherapy (RT), the patients used Noom, a health coaching mobile app that interactively provided online advice about food intake, exercise, and weight changes. The skeletal muscle index (SMI) measured based on computed tomography and nutrition-related laboratory markers were assessed before and after RT. We evaluated the changes in the SMI, nutrition, and inflammatory factors between the patient group that used the mobile app (mHealth group) and our previous study cohort (usual care group). Additionally, we analyzed the factors associated with walk steps recorded in the app. Results: Two patients dropped out of the study (no app usage; treatment changed to a definitive aim). The use (or activation) of the app was noted in approximately 70% (25/36) of the patients until the end of the trial. Compared to the 1:2 matched usual care group by propensity scores balanced with their age, primary tumor location, tumor stage, pre-RT BMI, and pre-RT SMI level, 30 operable patients showed less aggravation of the prognostic nutritional index (PNI) (–6.7 vs –9.8; P=.04). However, there was no significant difference in the SMI change or the number of patients with excessive muscle loss (∆SMI/50 days >10%). In patients with excessive muscle loss, the walk steps significantly decreased in the last 4 weeks compared to those in the first 4 weeks. Age affected the absolute number of walk steps (P=.01), whereas pre-RT sarcopenia was related to the recovery of the reduced walk steps (P=.03). Conclusions: For esophageal cancer patients receiving NACRT, a health care mobile app helped nutritional self-care with less decrease in the PNI, although it did not prevent excessive muscle loss. An individualized care model with proper exercise as well as nutritional support may be required to reduce muscle loss and malnutrition.